Semaglutide vs Survodutide
Semaglutide (GLP-1 receptor agonist) and Survodutide (Dual GLP-1/glucagon receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Semaglutide | Survodutide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | Dual GLP-1/glucagon receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | 31 amino acids | Not documented |
| Molecular weight | 4113.6 g/mol | Not documented |
| Half-life | ~7 days | ~6-7 days (~120-170 hours) |
| Origin | Developed by Novo Nordisk as a long-acting analog of the human incretin hormone GLP-1, building on the earlier once-daily liraglutide. It received first regulatory approvals in 2017 (injectable) and 2019 (oral). | An investigational dual agonist of the GLP-1 and glucagon receptors developed by Boehringer Ingelheim (also known as BI 456906). It has been evaluated in clinical trials in the 2020s. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Semaglutide works
Semaglutide is a structurally modified analog of native glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central appetite-regulating pathways to reduce food intake. Its backbone modifications and a C18 fatty-acid (diacid) side chain promote albumin binding and resistance to DPP-4 degradation, giving it a prolonged duration of action.
How Survodutide works
Survodutide is a synthetic peptide agonist that activates both the GLP-1 and glucagon receptors. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while glucagon-receptor agonism is proposed to raise energy expenditure and modulate hepatic metabolism. The combined action is being studied for effects on body weight and liver-related metabolic endpoints.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Semaglutide
Survodutide
What sets each apart
Semaglutide
Unlike dual or triple agonists, semaglutide is a selective GLP-1 receptor agonist. Its once-weekly dosing and availability in an oral form distinguish it from the older once-daily liraglutide.
Survodutide
Survodutide is a GLP-1/glucagon dual agonist (like mazdutide) rather than a GIP/GLP-1 agonist like tirzepatide, and has been notably studied for liver disease endpoints.
Frequently asked questions
What is semaglutide and what receptor does it target?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist derived from the native GLP-1 peptide with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin to extend its half-life. In research it is studied as a reference GLP-1 agonist in models of glucose regulation, appetite/food intake, and body-weight change. It is the mono-agonist against which many newer multi-receptor compounds are benchmarked.
What does semaglutide's long half-life mean for research design?
Semaglutide has a reported plasma half-life of roughly 7 days (about 155-184 hours), which is why once-weekly administration is used in the published literature. Steady-state concentrations are typically reached after about 4-5 weeks at a given dose level, so study designs generally include a multi-week dose-escalation before any maintenance-phase readout. This slow kinetics also means washout after discontinuation spans several weeks.
How is semaglutide dose-escalated in the research literature?
Published protocols use a stepwise weekly escalation, commonly 0.25 mg, then 0.5, 1.0, 1.7, and up to 2.4 mg once weekly, with each step typically held about 4 weeks. Escalation is used in the literature to reduce gastrointestinal tolerability issues rather than starting at the top dose. These are reference figures for research context only, not dosing guidance for humans.
How does survodutide differ from a GLP-1 mono-agonist?
Survodutide adds glucagon-receptor agonism on top of GLP-1 activity, which is why it is studied not only for body weight but also for metabolic dysfunction-associated steatohepatitis (MASH). A GLP-1 mono-agonist like semaglutide lacks that glucagon arm. The dual mechanism is the central research distinction.
What is survodutide and what receptors does it target?
Survodutide (BI 456906) is a dual glucagon-receptor / GLP-1-receptor agonist developed by Boehringer Ingelheim under license from Zealand Pharma. It is an acylated peptide carrying a C18 fatty-acid chain for half-life extension. In research the GLP-1 arm is associated with satiety and glucose effects while the glucagon arm is associated with energy expenditure and hepatic fat, and it is studied in obesity and MASH models.
What is survodutide's half-life and what does it imply for study design?
Survodutide has a reported half-life on the order of ~6-7 days (roughly 120-170 hours across sources), supporting once-weekly administration. Steady state is generally reached by about week 5 of weekly dosing, so protocols include a multi-week escalation before maintenance readouts. The long half-life also means a multi-week washout after discontinuation.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.